Therapeutic effect of metformin in rectal cancer

The Evaluation of the Effect of Metformin on Pathologic Complete Response (pCR) to Chemoradiotherapy of Rectal Cancer in Non-Diabetic Patients

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190726044335N1

Enrollment

Registered

2019-08-20

Start date

2019-08-23

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal cancer. Malignant neoplasm of rectum

Interventions

Intervention 1: Intervention group: The patients with rectal cancer in the case group will be taken the metformin 500 mg Po Bid after eating and taking into account the contraindications. Intervention

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: All non-diabetic patients with rectal adenocarcinoma aged 18 to 75 y/o and performance status <2

Exclusion criteria

Exclusion criteria: Treatment with surgery or radiation alone, distant metastasis, previous pelvic radiotherapy, and hypersensitivity reaction to the medications

Design outcomes

Primary

Measure	Time frame
Pathologic complete response. Timepoint: Post operation. Method of measurement: Pathologic examination.	—

Secondary

Measure	Time frame
Side effects. Timepoint: Weekly during intervention course. Method of measurement: Radiation therapy oncology group toxicity criteria.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMonireh Jelodari

Shiraz University of Medical Sciences

mjelodari@sums.ac.ir+98 71 3647 4320

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026